Table 3 Histopathological parameters and relative expression levels of galectin-1/3 mRNA in all patients with RCC
From: Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma
Sample/pathology | n | Mean relative expression (ΔΔCt) | SD |
|---|---|---|---|
LGALS1 | 106 | ||
Male | 68 | 1.58 | 0.87 |
Female | 38 | 1.37 | 0.91 |
Age (< median) | 54 | 1.50 | 0.96 |
Age (≥ median) | 52 | 1.48 | 0.81 |
M0 | 83 | 1.41 | 0.90 |
M+ | 23 | 1.77 | 0.78 |
N0 | 95 | 1.44 | 0.86 |
N+ | 11 | 1.97 | 1.03 |
Localized RCC* | 57 | 1.34 | 0.89 |
Advanced RCC* | 49 | 1.67 | 0.86 |
Grade (≤2) | 89 | 1.46 | 0.85 |
Grade (> 2) | 17 | 1.63 | 1.09 |
LGALS3 | 105 | ||
Male | 38 | -0.41 | 1.04 |
Female | 67 | -0.06 | 0.79 |
Age (< median) | 54 | -0.25 | 0.97 |
Age (≥ median) | 51 | -0.12 | 0.82 |
M0 | 82 | -0.18 | 0.90 |
M+ | 23 | -0.23 | 0.92 |
N0 | 94 | -0.21 | 0.86 |
N+ | 11 | -0.001 | 1.23 |
Localized RCC* | 56 | -0.13 | 0.91 |
Advanced RCC* | 49 | -0.25 | 0.89 |
Grade (≤ 2) | 88 | -1.62 | 0.9 |
Grade (> 2) | 17 | -0.43 | 0.91 |